What is BIIB's current stock price?

As of now, BIIB is trading at $154.27, with a daily change of +3.11%.

What is BIIB next earnings date?

BIIB next earnings report is scheduled for Oct 29, 2025.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

BIIB Stock Analysis & IQ Rating | Biogen

BIIB

Biogen

$154.27

+$4.66 | +3.11%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 179.2

MKT CAP

$ 22.72B

52W Low

$ 110.04

VOL

$ 2.17M

P/E Ratio

14.76

AVG VOL

$ 1.71M

RSI

63.32

TREND

Uptrend

BIIB Stock IQ

Login to see Biogen (BIIB) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

BIIB Target Price

Login to display

Strengths

BIIB Rewards

Earnings are forecast to grow

BIIB Rewards

Trading below its fair value

BIIB Rewards

Outperform the market

Chart

$154.05 (+0.14%)

$130.67 (+18.06%)

$133.06 (+15.94%)

$164.89 (-6.44%)

1year

6month

3month

1month

BIIB Risk Level

BIIB has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Low

LOW

HIGH

BIIB Analysts Opinion

BIIB overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

BIIB Analysts Opinion

BIIB Analysts opinion is negative and it remained unchanged from the past 3 months

BIIB Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

70%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

33%

50%

BIIB Street Opinion

BIIB Street view is bullish but have mixed views on the near-term outlook

BIIB Performance Sentiment

Sentiments overview associated with BIIB events and the stock performance.

70%

30%

Positive

Negative

16 out of 23
events present

7 out of 23
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$149.91

Resistance
Price

$137.37

Current Price Range

$159.88

Show methods +

BIIB Earnings

The TTM reflects 12-month period, providing review of BIIB financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

9,997

9,676

9,836

+0.82%

Cost of Revenue

2,457

2,310

2,533

-1.51%

Gross Profit

7,541

7,366

7,302

+1.62%

Operating Exp

5,133

5,147

5,471

-3.14%

Operating Inc

2,408

2,219

1,831

+14.68%

Net Interest Inc

-166

-183

30

-

Interest Exp

252

250

247

+1.01%

Interest Inc

86

68

277

-44.28%

Other Inc Exp

-444

-130

-564

-

EPS Growth

10.15

11.21

8.02

+12.50%

BIIB Financial Health

The company financial health has moderately improved over the past year

Financial Score

3.57

Next Earnings Date: Oct 29, 2025

Linked to BIIB

IQ

Close Price

Change

AMGN

3.85

298.43

+2.20%

SCLX

2.75

16.50

-8.59%

CHRS

3.50

1.68

-1.18%

ALVO

2.25

7.65

-2.42%

BIIB Latest Analysis +

BIIB Beats on Q3 Earnings & Sales Stock Down on Lowered 25 EPS View. Biogens Q3 earnings and sales top estimates on strong drug demand but shares slide after the company cuts its 2025 EPS forecast.

Thu Oct 30, 2025

$149.61 | +1.18%

Earnings

Momentum

Biogen lowers 2025 EPS guidance despite Q3 beats.

Thu Oct 30, 2025

$149.61 | +1.18%

Potential

Biogen Non-GAAP EPS of $4.81 beats by $0.93 revenue of $2.54B beats by $200M.

Thu Oct 30, 2025

$149.61 | +1.18%

Earnings

Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide. Biogen stock fell early Thursday after the biotech company cut its 2025 profit outlook due to an expected tax charge.The post Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide appeared first on Investor'.s Business Daily.

Thu Oct 30, 2025

$149.61 | +1.18%

Momentum

Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates. Biogen (BIIB) delivered earnings and revenue surprises of 23.65% and 8.31% respectively for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Thu Oct 30, 2025

$149.61 | +1.18%

Earnings

Biogen Inc. Q3 Profit Increases Beats Estimates . (RTTNews) - Biogen Inc. (BIIB) announced a profit for its third quarter that Increased from last year and beat the Street estimates.

Thu Oct 30, 2025

$149.61 | +1.18%

Earnings

Biogen Q3 Beats Market Cuts FY25 Earnings View Below Street - Update . (RTTNews) - Biotechnology company Biogen Inc. (BIIB) while reporting higher third-quarter results above market estimates on Thursday trimmed fiscal 2025 earnings forecast below the Street. Further the company raised revenue growth view.

Thu Oct 30, 2025

$149.61 | +1.18%

Earnings

Biogens Immunology Pipeline Has Long-Term Potential: Analyst. On Friday BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua'.s preclinical oral C5aR1 antagonist. The agreement strengthens .BIIB stock is taking a breather. The agreement complements Biogen'.s early-stage immunology pipeline by adding an oral mechanism with potential applicability across multiple immune-mediated diseases.C5aR1 plays a pivotal role in driving critical compo

Fri Oct 24, 2025

$149.91 | -0.13%

Activity

Potential

Biogen Vanqua ink licensing deal worth up to $1B for immunology drug.

Fri Oct 24, 2025

$149.91 | -0.13%

Activity

Will Biogen Beat on Q3 Earnings? Leqembi Skyclarys Could Hold the Key. Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.

Fri Oct 24, 2025

$149.91 | -0.13%

Activity

Momentum

Potential

FAQ About BIIB Stock Insights

What is BIIB current stock price?

What are BIIB stock strengths?

What risks are associated with BIIB stock?

When is BIIB next earnings report?

What is BIIB market cap and volume?

What is BIIB's current Stock IQ?

Should I buy BIIB stock right now?

Is BIIB a Strong Buy right now?

What does a 'Strong Buy' rating mean for BIIB?

What does a 'Strong Sell' rating mean for BIIB?

What factors influence BIIB's Stock IQ?

Explore our BIIB Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored BIIB Stock Strategies
Effective Risk Management

FIND US ON

Receive our BIIB Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

BIIB

Biogen

Current Price

$154.27

+$4.66 | +3.11%

52W High

$ 179.2

MKT CAP

$ 22.72B

52W Low

$ 110.04

VOL

$ 2.17M

P/E Ratio

14.76

AVG VOL

$ 1.71M

RSI

63.32

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

BIIB Rewards

Earnings are forecast to grow

BIIB Rewards

Trading below its fair value

BIIB Rewards

Outperform the market

Linked to BIIB

Symbol

IQ

Close

Change

AMGN

3.85

298.43

+2.20%

SCLX

2.75

16.50

-8.59%

CHRS

3.50

1.68

-1.18%

ALVO

2.25

7.65

-2.42%

BIIB Stock IQ

Login to unlock Biogen (BIIB) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$154.05 (+0.14%)

$130.67 (+18.06%)

$133.06 (+15.94%)

$164.89 (-6.44%)

1year

6month

3month

1month

BIIB Analysts Opinion

BIIB Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

BIIB Analysts Opinion

BIIB Analysts opinion is negative and it remained unchanged from the past 3 months

BIIB Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

70%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

33%

50%

BIIB Street Opinion

BIIB Street view is bullish but have mixed views on the near-term outlook

BIIB Risk Level

BIIB has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Low

LOW

HIGH

BIIB Performance Sentiment

Sentiments overview associated with BIIB events and the stock performance.

70%

30%

Positive

Negative

16 out of 23
events present

7 out of 23
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$149.91

Resistance
Price

$137.37

Current Price Range

$159.88

Show methods +

BIIB Earnings

The TTM data reflects the most recent 12-month period, providing overview of BIIB financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

9,997

9,676

9,836

+0.82%

Cost of Revenue

2,457

2,310

2,533

-1.51%

Gross Profit

7,541

7,366

7,302

+1.62%

Operating Exp

5,133

5,147

5,471

-3.14%

Operating Inc

2,408

2,219

1,831

+14.68%

Net Interest Inc

-166

-183

30

-

Interest Exp

252

250

247

+1.01%

Interest Inc

86

68

277

-44.28%

Other Inc Exp

-444

-130

-564

-

EPS Growth

10.15

11.21

8.02

+12.50%

BIIB Financial Health

The company financial health has moderately improved over the past year

Financial Score

3.57

Next Earnings Date: Oct 29, 2025

BIIB Latest Analysis

BIIB Beats on Q3 Earnings & Sales Stock Down on Lowered 25 EPS View. Biogens Q3 earnings and sales top estimates on strong drug demand but shares slide after the company cuts its 2025 EPS forecast.

Thu Oct 30, 2025

$149.61 | +1.18%

Earnings

Momentum

Biogen lowers 2025 EPS guidance despite Q3 beats.

Thu Oct 30, 2025

$149.61 | +1.18%

Potential

Biogen Non-GAAP EPS of $4.81 beats by $0.93 revenue of $2.54B beats by $200M.

Thu Oct 30, 2025

$149.61 | +1.18%

Earnings

Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide. Biogen stock fell early Thursday after the biotech company cut its 2025 profit outlook due to an expected tax charge.The post Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide appeared first on Investor'.s Business Daily.

Thu Oct 30, 2025

$149.61 | +1.18%

Momentum

Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates. Biogen (BIIB) delivered earnings and revenue surprises of 23.65% and 8.31% respectively for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Thu Oct 30, 2025

$149.61 | +1.18%

Earnings

Biogen Inc. Q3 Profit Increases Beats Estimates . (RTTNews) - Biogen Inc. (BIIB) announced a profit for its third quarter that Increased from last year and beat the Street estimates.

Thu Oct 30, 2025

$149.61 | +1.18%

Earnings

Biogen Q3 Beats Market Cuts FY25 Earnings View Below Street - Update . (RTTNews) - Biotechnology company Biogen Inc. (BIIB) while reporting higher third-quarter results above market estimates on Thursday trimmed fiscal 2025 earnings forecast below the Street. Further the company raised revenue growth view.

Thu Oct 30, 2025

$149.61 | +1.18%

Earnings

Biogens Immunology Pipeline Has Long-Term Potential: Analyst. On Friday BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua'.s preclinical oral C5aR1 antagonist. The agreement strengthens .BIIB stock is taking a breather. The agreement complements Biogen'.s early-stage immunology pipeline by adding an oral mechanism with potential applicability across multiple immune-mediated diseases.C5aR1 plays a pivotal role in driving critical compo

Fri Oct 24, 2025

$149.91 | -0.13%

Activity

Potential

Biogen Vanqua ink licensing deal worth up to $1B for immunology drug.

Fri Oct 24, 2025

$149.91 | -0.13%

Activity

Will Biogen Beat on Q3 Earnings? Leqembi Skyclarys Could Hold the Key. Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.

Fri Oct 24, 2025

$149.91 | -0.13%

Activity

Momentum

Potential

Discover BIIB Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of BIIB. We're here to help you make informed investment decisions today.

FIND US ON

Receive our BIIB Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

BIIB Stock trends

BIIB Stock performance

BIIB Stock analysis

BIIB investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BIIB

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BIIB

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

BIIB Stock Analysis & IQ Rating | Biogen

BIIB Stock IQ

BIIB Target Price

BIIB Risk Level

BIIB Analysts Opinion

BIIB Street Consensus

BIIB Performance Sentiment

Technical Price Levels

BIIB Financial Health

Explore our BIIB Stock insights

Receive our BIIB Daily Alerts

BIIB Stock IQ

BIIB Street Consensus

BIIB Risk Level

Technical Price Levels

Discover BIIB Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of BIIB. We're here to help you make informed investment decisions today.

Receive our BIIB Daily Alerts

BIIB Runner Alarm